Retinal toxicity secondary to Plaquenil therapy

Betty Hanna, Nicky R. Holdeman, Rosa A. Tang, Jade S. Schiffman

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Background: Hydroxychloroquine sulfate (Plaquenil; Sanofi-Aventis, Bridgewater, New Jersey) is an antimalarial agent, which is sometimes used for the treatment of certain autoimmune disorders. Its use has been associated with ocular side effects; the most concerning is toxic maculopathy. Case report: A 71-year-old arthritic white woman requested a second opinion regarding retinal Plaquenil toxicity. The patient°Fs history was significant for seronegative rheumatoid arthritis diagnosed 6 years prior. She had taken Plaquenil 400 mg a day for about 5 years but had discontinued the drug 6 months before when bilateral central scotomas were first noted. At the consultation visit, her visual acuities were 20/20 in both eyes. SITA-Standard 10-2 disclosed a dense scotoma with 4° of central sparing in each eye. Fundus examination found retinal pigment epithelium changes bilaterally; no "bull°Fs eye" retinopathy was observed. Conclusion: Withdrawal of the medication is the only effective treatment for Plaquenil toxicity and, even then, the toxic effects may progress because of the slow clearance of the drug. Though controversy exists regarding screening recommendations, a baseline ophthalmic examination should be performed on all patients before initiating Plaquenil. If a patient is considered low risk, examinations can be scheduled annually. For high-risk patients, 6-month progress visits are strongly recommended.

Original languageEnglish (US)
Pages (from-to)90-94
Number of pages5
JournalOptometry
Volume79
Issue number2
DOIs
StatePublished - Feb 2008

Keywords

  • Bull°Fs eye maculopathy
  • Fundus autofluorescence
  • Hydroxychloroquine
  • Multifocal electroretinogram
  • Plaquenil toxicity
  • Threshold Amsler grid

ASJC Scopus subject areas

  • Health Professions(all)

Fingerprint Dive into the research topics of 'Retinal toxicity secondary to Plaquenil therapy'. Together they form a unique fingerprint.

Cite this